ClinicalTrials HQ

Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).

Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).

Recruiting · NCT06751238 · Registry updated 2026-09-28
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).Skin and Connective Tissue Diseases, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, immune system disorder, juvenile idiopathic arthritis, musculoskeletal system disorder, rheumatic disorderRecruitingPhase 12026-09-28NCT06751238

1 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
Novartis Pharmaceuticals432

11 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Ann and Robert H Lurie Childs HospChicagoUnited States2
Childrens Hosp Pittsburgh UPMCPittsburghUnited States4
Cincinnati Childrens HospitalCincinnatiUnited States9
Col Uni Med Center New York PresbyNew YorkUnited States6
Legacy Emanuel Research Hosp PortlandPortlandUnited States2
Levine Childrens HospitalCharlotteUnited States1
Loma Linda University HealthLoma LindaUnited States24
Texas Arthritis CenterEl PasoUnited States7
Univ Hosp Cleveland Medical CenterClevelandUnited States3
University of FloridaGainesvilleUnited States1
University of UtahSalt Lake CityUnited States16